Genmab — Maj 2018
-
Selv om jeg er helt enig i, at Genmab ikke er ansvarlig for markedets reaktioner på pressemeddelelsen så er problemet vel alligevel lidt det, at et problem for PD1 opfattes som et problem for Dara (se blot Bowers mærkelige udlægning). . Det kunne man godt have undgået med en lidt anden ordlyd
-
Jeg ved ikke rigtig i hvilket omfang Jan har hypet Dara i fste tumorer. Syntes mere at hans primære fokus har været andet steds:https://medwatch.dk/secure/Medicinal___Biotek/article10024820.ece
-
I think it is necessary to get an assessment of data and mechanisms associated with the study of small cell lung cancer before Janssen will judge Dara out
in solid tumors. -
and AXL is 100% Genmab owned!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind